共 50 条
- [31] Correction to: Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)International Journal of Clinical Oncology, 2020, 25 : 1744 - 1745Tomoro HishikiKimikazu MatsumotoMiki OhiraTakehiko KamijoHiroyuki ShichinoTatsuo KurodaAkihiro YonedaToshinori SoejimaAtsuko NakazawaTetsuya TakimotoIsao YokotaSatoshi TeramukaiHideto TakahashiTakashi FukushimaTakashi KanekoJunichi HaraMichio KanekoHitoshi IkedaTatsuro TajiriAkira Nakagawara
- [32] Treatment results in childhood acute lymphoblastic leukemia with a modified ALL-BFM'90 protocol: lack of improvement in high-risk groupLEUKEMIA RESEARCH, 1999, 23 (04) : 331 - 340Sackmann-Muriel, FFelice, MSZubizarreta, PAAlfaro, EGallego, MRossi, JCygler, AM
- [33] A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (02): : 294 - 302Rosenthal, Seth A.Hunt, DanielSartor, OliverPienta, Kenneth J.Gomella, LeonardGrignon, DavidRajan, RaghuKerlin, Kevin J.Jones, Christopher U.Dobelbower, MichaelShipley, William U.Zeitzer, KennethHamstra, Daniel A.Donavanik, ViroonRotman, MarvinHartford, Alan C.Michalski, JeffreySeider, MichaelKim, HaroldKuban, Deborah A.Moughan, JenniferSandler, Howard
- [34] High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch childhood leukemia study groupJOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 911 - 918Veerman, AJPHahlen, KKamps, WAVanLeeuwen, EFDeVaan, GAMSolbu, GSuciu, SVanWering, ERVanderDoesVandenBerg, A
- [35] Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Gronchi, AlessandroPalmerini, EmanuelaQuagliuolo, VittorioBroto, Javier MartinPousa, Antonio LopezGrignani, GiovanniBrunello, AntonellaBlay, Jean-YvesBeveridge, Robert DiazFerraresi, VirginiaLugowska, IwonaMerlo, Franco DomenicoFontana, ValeriaPalassini, ElenaMorosi, CarloStacchiotti, SilviaDei Tos, Angelo PaoloPicci, PieroBruzzi, PaoloCasali, Paolo Giovanni
- [36] Treatment Reduction in Patients with Advanced-Stage Hodgkin Lymphoma and Negative Interim FDG-PET: Final Results of the International, Randomized, Phase 3 HD18 Trial by the German Hodgkin Study GroupEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S312 - S312Kobe, C.Goergen, H.Fuchs, M.Eich, H. T.Baues, C.Diehl, V.Kuhnert, G.Drzezga, A.Dietlein, M.Engert, A.Borchmann, P.
- [37] PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 by the GHSGINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S1 - S1Eich, H. T.Baues, C.Fuchs, M.Kobe, C.Greil, R.Sasse, S.Zijlstra, J. M.Lohri, A.Rosenwald, A.Tresckow, B. V.Diehl, V.Kuhnert, G.Dietlein, M.Borchmann, P.Engert, A.
- [38] PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupLANCET, 2017, 390 (10114): : 2790 - 2802Borchmann, PeterGoergen, HelenKobe, CarstenLohri, AndreasGreil, RichardEichenauer, Dennis A.Zijlstra, Josee M.Markova, JanaMeissner, JuliaFeuring-Buske, MichaelaHuttmann, AndreasDierlamm, JudithSoekler, MartinBeck, Hans-JoachimWillenbacher, WolfgangLudwig, Wolf-DieterPabst, ThomasTopp, Max S.Hitz, FelicitasBentz, MartinKeller, Ulrich BerndKuhnhardt, DagmarOstermann, HelmutSchmitz, NorbertHertenstein, BerndAulitzky, WalterMaschmeyer, GeorgVieler, TomEich, HansBaues, ChristianStein, HaraldFuchs, MichaelKuhnert, GeorgDiehl, VolkerDietlein, MarkusEngert, Andreas
- [39] Final results of the AGO breast cancer study group MAMMA-3 trial:: first-line capecitabine plus paclitaxel vs epirubicin plus paclitaxel for high-risk metastatic breast cancerBREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S67 - S67Lueck, H-Jdu Bois, A.Schrade, IHuober, J.Heilmann, VFasching, P. A.Staehle, A.Jackisch, C.Marth, C.Richter, B.von Minckwitz, G.